BPC-157 has mostly animal evidence and a sparse human record: FDA's May 2026 review identified five small human reports or studies, including placebo-controlled and randomized meeting abstracts, a retrospective knee-pain review, a single-arm interstitial-cystitis report, and a two-person safety pilot; their designs, reporting, and outcomes do not establish efficacy. TB-500 generally refers to a seven-amino-acid fragment, Ac-LKKTETQ, rather than the 43-amino-acid parent peptide thymosin beta-4; human thymosin beta-4 studies therefore cannot be relabeled as TB-500 studies. As of 2026-09-11, FDA records reviewed for this brief show no FDA-approved human drug containing either substance, and the 2026 compounding review had not become a final FDA approval or 503A listing.
Start with the molecules, not the marketing names
BPC-157, also called body protection compound 157, is reported by FDA as a synthetic peptide made of 15 amino acids. FDA evaluated both BPC-157 free base and BPC-157 acetate as distinct bulk drug substances because a salt form is not automatically interchangeable with the free-base form. In other words, the shared label “BPC-157” does not by itself identify one standardized finished product.[1]
TB-500 is a less precise common name. In the FDA evaluation, TB-500 free base is understood as a synthetic seven-amino-acid fragment corresponding to residues 17–23 of thymosin beta-4, with an N-terminal acetyl group: Ac-LKKTETQ. FDA also found that different salts and derivatives can be sold under the same common name. The name is not a guarantee that two products contain the same active molecule.[2][11]
Full-length thymosin beta-4, often written Tβ4, is a separate 43-amino-acid peptide. Its sequence was established in early biochemical work, while TB-500 is a shorter fragment based on part of that sequence. A biological finding with full-length Tβ4 is therefore not automatically evidence for the TB-500 fragment, even when a paper discusses a related actin-binding region.[9][10][11]
What BPC-157 studies have actually measured
The classic BPC-157 healing literature is preclinical, meaning it studies cells or animals rather than people. In one primary rat experiment, researchers examined skin incisions, colon-to-colon connections, and a sponge model of new blood-vessel formation. They reported differences in tissue measures such as collagen, reticulin, blood vessels, and wound strength between treated animals and controls. Those findings describe experimental models; they do not establish a clinical effect in people.[5]
A separate preclinical safety paper examined BPC-157 in mice, rats, rabbits, and dogs. The authors reported no serious toxicity in those experiments, with mild local irritation and a creatinine change in one repeated-exposure dog group noted in the abstract. Animal tolerability can guide further research, but it cannot substitute for a controlled human safety study, and the paper did not establish a human treatment benefit.[6]
FDA's May 11, 2026 review identified five small human reports or studies, but they are not one coherent efficacy program: placebo-controlled phase 1 tolerability and pharmacokinetics meeting abstracts in healthy volunteers; a 53-subject randomized, double-blind, placebo-controlled ulcerative-colitis meeting abstract, with 46 completing and limited outcome detail; a retrospective chart review of 17 people identified with knee pain, with some BPC-157 use combined with thymosin beta-4; a single-arm report in 12 women with moderate-to-severe interstitial cystitis; and a two-person healthy-adult pilot that recorded short-term clinical observations. The abstracts and small observational reports have limited reporting and cannot establish efficacy. A separate ClinicalTrials.gov record for an earlier phase 1 BPC-157 safety and pharmacokinetics study is listed with an unknown status and no posted results in the retrieved record.[1][7][8]
TB-500 fragment evidence is not full-length Tβ4 evidence
A primary 2003 mouse study tested full-length thymosin beta-4 and a synthetic seven-amino-acid peptide, LKKTETQ, in wound models. In aged mice, the short peptide produced a wound-repair endpoint comparable to the parent molecule in that experiment. This is useful evidence that a fragment can be studied separately, but it is still an animal result and it does not establish that a marketed TB-500 preparation is identical to the tested peptide or works in humans.[10]
A separate analytical study identified the N-terminal-acetylated fragment Ac-LKKTETQ in a product called TB-500 and synthesized that fragment for laboratory detection. That study established chemical identity and an analytical method; it was not a clinical efficacy trial. The distinction matters because full-length Tβ4, LKKTETQ, Ac-LKKTETQ, and acetate salt forms are not interchangeable names for one tested intervention.[11]
Human studies cited in discussions of Tβ4 include a small randomized, double-masked, placebo-controlled phase 2 trial of RGN-259 eye drops in nine people with severe dry eye. The paper reported differences in ocular discomfort and corneal staining at some time points. RGN-259 was identified in the paper as thymosin beta-4 eye drops, not TB-500; an eye study of the full-length parent peptide cannot be used as a TB-500 trial.[12]
Visit the store directly, or keep exploring the evidence library. No email signup is needed to visit the store.
What the human evidence can—and cannot—say
FDA's May 11, 2026 BPC-157 evaluation identified five human reports or studies: a placebo-controlled phase 1 tolerability and pharmacokinetics study reported in meeting abstracts among healthy volunteers; a 53-subject randomized, double-blind, placebo-controlled ulcerative-colitis meeting abstract, with 46 completing; a retrospective knee-pain chart review involving 17 identified people, with some use combined with thymosin beta-4; a single-arm report in 12 women with moderate-to-severe interstitial cystitis; and a two-person healthy-adult pilot. These differ in population, design, comparator, reporting quality, and outcomes. FDA described the ulcerative-colitis abstract as difficult to interpret because details were limited and the study was exploratory; the retrospective and single-arm reports cannot control for selection, placebo, natural history, or co-interventions. The two-person pilot reported short-term observations, not efficacy. A separate older phase 1 registry record has unknown status and no posted results. Together, these records do not establish effectiveness or long-term safety.[1][5][6][7][8]
For TB-500, FDA's 2026 review reported that its literature search did not identify clinical studies or human exposure data using TB-500 free base or TB-500 acetate. FDA also did not identify in-vivo animal pharmacology studies assessing these TB-500 substances for wound healing in the reviewed record. Some fragment and parent-peptide experiments exist, but they cannot fill the specific human TB-500 gap.[2][10][11]
There is no cited head-to-head clinical trial that assigns people to BPC-157 or TB-500 and measures the same condition, outcome, and follow-up. The five varied BPC-157 human records, a rat wound endpoint, a full-length Tβ4 eye study, and the absence of TB-500 human data are different kinds of evidence. Putting them in one table can clarify the differences; it cannot produce a scientifically valid winner or treatment ranking.[1][2][7][8][12]
Safety, product quality, and U.S. status
FDA's May 11, 2026 BPC-157 evaluation said neither BPC-157 free base nor BPC-157 acetate was a component of an FDA-approved drug and found no applicable USP or National Formulary drug-substance monograph. FDA's May 15, 2026 TB-500 evaluation said the same for TB-500 free base and acetate. These statements describe regulatory status; they are not findings that an online, dietary-supplement, or compounded product has been reviewed for safety or effectiveness.[1][2]
Both FDA evaluations raised quality and safety uncertainties involving inconsistent naming, incomplete impurity and aggregate controls, and possible immunogenicity—the potential for a peptide or its impurities to trigger an immune response. For TB-500, FDA found no human clinical safety data and said human risks were unknown. For BPC-157, FDA said the available ulcerative-colitis evidence was insufficient and noted that many nonclinical studies did not clearly identify the free-base or acetate form.[1][2]
As of 2026-09-11, the dated U.S. record reviewed here supports describing both substances as investigational and not FDA-approved for a human indication. FDA's July 2026 PCAC briefing said the agency would not issue a final determination on the 503A bulk-drug-list questions until the advisory process and reviews were completed. The related Regulations.gov docket is identified as a nonrulemaking docket. An advisory discussion or recommendation is not an FDA drug approval, a final rule, or a quality certification.[3][4]
How to read the comparison
The most important question is not which name sounds more regenerative; it is which exact molecule was studied, in what species, for which outcome, against what comparator, and for how long. “Wound healing” can refer to a microscopic, animal, or patient-reported endpoint. “Human evidence” can refer to a small safety observation, a controlled clinical outcome, or evidence for a different molecule. Those categories should stay separate.[1][2][5][7][10][12]
The fair bottom line is limited and descriptive: BPC-157 has a much larger preclinical literature than human clinical evidence, while FDA's 2026 review identified five small, heterogeneous human reports or studies and judged the ulcerative-colitis evidence insufficient. The TB-500 name refers to a fragment whose human evidence was not identified by FDA. Full-length Tβ4 has separate human studies, but they do not answer the TB-500 question. Neither evidence base supplies a head-to-head comparison or supports promises about general recovery, performance, or wellness.[1][2][5][7][10][12]
At a glance
| Topic | BPC-157 | TB-500 |
|---|---|---|
| What the name refers to[1][2][11] | A reported 15-amino-acid synthetic peptide; FDA separately evaluated free-base and acetate forms. | Usually a seven-amino-acid fragment, Ac-LKKTETQ, but FDA found that the common name can cover different salts or derivatives. |
| Relationship to full-length Tβ4[2][9][11] | Not a thymosin beta-4 fragment. | Based on residues 17–23 of the distinct 43-amino-acid parent peptide; it is not full-length Tβ4. |
| Strongest cited BPC/TB-500-specific evidence[1][2][5][6][7][10][11] | Rat healing experiments and animal safety studies; FDA also identified five small human reports or studies, but their meeting-abstract, retrospective, single-arm, and pilot designs do not establish efficacy. | An animal experiment involving the seven-amino-acid fragment and a chemical-identification study; FDA found no human TB-500 clinical study. |
| Human evidence boundary[1][2][7][8][12] | FDA's five reports include placebo-controlled healthy-volunteer tolerability and pharmacokinetics abstracts; a 53-subject randomized, double-blind ulcerative-colitis meeting abstract with 46 completing and limited outcome detail; a 17-person retrospective knee-pain review; a 12-woman single-arm interstitial-cystitis report; and a two-person healthy-adult pilot. Their different populations, designs, and limited reporting prevent an efficacy conclusion; a separate phase 1 registry record has no posted results. | No human TB-500 clinical or exposure data were identified by FDA. Human full-length Tβ4 studies are a different evidence base. |
| U.S. regulatory status on 2026-09-11[1][2][3][4] | No FDA-approved human drug containing BPC-157; the May 2026 FDA evaluation weighed against 503A-list inclusion. | No FDA-approved human drug containing TB-500; the May 2026 FDA evaluation weighed against 503A-list inclusion. |
| Can one be ranked against the other?[1][2][7][8][10][12] | No. The cited studies do not provide a shared population, intervention, outcome, and follow-up for comparison. | No. TB-500 fragment data and full-length Tβ4 data cannot be substituted for a head-to-head trial. |
Questions readers ask
Is TB-500 the same molecule as full-length thymosin beta-4?
No. Full-length thymosin beta-4 is a 43-amino-acid peptide. FDA describes TB-500 free base as a seven-amino-acid fragment, Ac-LKKTETQ, and also warns that the common name can be used for different salts or derivatives. A full-length Tβ4 study should not be labeled a TB-500 study.[2][9][11]
Do animal results prove that BPC-157 or TB-500 works in people?
No. BPC-157 rat studies and the mouse fragment study measured experimental healing outcomes in animals. Species, formulation, exposure, injury model, and outcome can all differ from a human trial. Animal findings can motivate research, but they do not establish a human clinical benefit.[5][10]
What human evidence exists for BPC-157?
FDA's May 11 review identified five small human reports or studies: placebo-controlled phase 1 tolerability and pharmacokinetics meeting abstracts in healthy volunteers; a 53-subject randomized, double-blind, placebo-controlled ulcerative-colitis meeting abstract with 46 completing and limited outcome detail; a retrospective chart review of 17 people with knee pain, with some use combined with thymosin beta-4; a single-arm report of 12 women with moderate-to-severe interstitial cystitis; and a two-person healthy-adult pilot with short-term safety observations. These are not one consistent efficacy program: the abstracts have limited reporting, while retrospective, single-arm, and pilot designs lack robust comparators or are too small to establish effectiveness. An older phase 1 ClinicalTrials.gov record has unknown status and no posted results.[1][7][8]
Is either BPC-157 or TB-500 FDA-approved?
No FDA-approved human drug containing either substance was identified in the FDA records reviewed for this brief. FDA's May 2026 evaluations say neither substance is a component of an FDA-approved drug. The July 2026 compounding committee process and its docket do not equal drug approval or a final 503A-list rule.[1][2][3][4]
Can the RGN-259 thymosin beta-4 trial be used as evidence for TB-500?
No. The RGN-259 paper studied thymosin beta-4 eye drops in people with severe dry eye. That is full-length parent-peptide evidence in a specific eye condition, not a trial of the TB-500 fragment, and it cannot establish TB-500's safety or effectiveness.[9][12]
Sources
References
- FDA Evaluation of BPC-157-Related Bulk Drug Substances (BPC-157 free base and BPC-157 acetate)U.S. Food and Drug Administration, Pharmacy Compounding Advisory Committee briefing document dated May 11, 2026; identity, regulatory status, effectiveness review, and product-quality and safety concerns. FDA's clinical-evidence appendix identifies five small human reports or studies: placebo-controlled healthy-volunteer tolerability/pharmacokinetics meeting abstracts, a 53-subject randomized double-blind ulcerative-colitis meeting abstract, a 17-person retrospective knee-pain review, a 12-woman single-arm interstitial-cystitis report, and a two-person healthy-adult pilot. Their limited reporting and differing designs do not establish efficacy.
- FDA Evaluation of TB-500-Related Bulk Drug Substances (TB-500 free base and TB-500 acetate)U.S. Food and Drug Administration, Pharmacy Compounding Advisory Committee briefing document dated May 15, 2026; fragment identity, absence of identified human TB-500 studies, effectiveness review, and quality and safety concerns.
- FDA Briefing Document: Pharmacy Compounding Advisory Committee Meeting, July 23–24, 2026FDA meeting briefing document explaining the 503A bulk-drug-list process and stating that the agency's final determination would follow advisory input and completion of reviews.
- Pharmacy Compounding Advisory Committee; Notice of Meeting and Public Docket (FDA-2025-N-6895)Official Regulations.gov docket created by FDA; identified as a nonrulemaking docket for the July 2026 advisory meeting, with comments closed July 22, 2026.
- BPC 157's effect on healingSeiwerth et al., Journal of Physiology-Paris, 1997;91(3–5):173–178; primary rat models of skin wounds, colon anastomoses, and angiogenesis-related tissue outcomes.
- Preclinical safety evaluation of body protective compound-157, a potential drug for treating various woundsXu et al., Regulatory Toxicology and Pharmacology, 2020;114:104665; primary preclinical toxicity and local-tolerance studies in mice, rats, rabbits, and dogs.
- Safety of Intravenous Infusion of BPC157 in Humans: A Pilot StudyLee and Burgess, Alternative Therapies in Health and Medicine, 2025;31(5):20–24; two-participant human pilot recording short-term observations, without a randomized efficacy comparison.
- PCO-02 – Safety and Pharmacokinetics Trial (NCT02637284)ClinicalTrials.gov phase 1 registry record for a planned BPC-157 safety and pharmacokinetics study in healthy volunteers; retrieved record lists unknown status and no posted results.
- Chemical characterization of thymosin beta 4Low and Goldstein, Journal of Biological Chemistry, 1982;257(2):1000–1006; primary biochemical characterization establishing the 43-amino-acid thymosin beta-4 sequence.
- Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged micePhilp et al., Wound Repair and Regeneration, 2003;11(1):19–24; primary animal study comparing full-length Tβ4 with a seven-amino-acid LKKTETQ peptide.
- Synthesis and characterization of the N-terminal acetylated 17–23 fragment of thymosin beta 4 identified in TB-500Esposito et al., Drug Testing and Analysis, 2012;4(9):733–738; primary analytical identification and synthesis of Ac-LKKTETQ.
- Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trialSosne et al., Cornea, 2015;34(5):491–496; small randomized, double-masked, placebo-controlled human trial of RGN-259 thymosin beta-4 eye drops, not TB-500.